Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Chemed authorizes additional $250M for stock repurchase » 11:31
03/13/20
03/13
11:31
03/13/20
11:31
CHE

Chemed

$385.28 /

+2.91 (+0.76%)

Chemed announced that the…

Chemed announced that the board of directors has formally authorized an additional $250M for stock repurchase under Chemed's existing share repurchase program. These share repurchases will be funded through a combination of cash generated from operations as well as utilization of its revolving credit facility, the company said.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Chemed upgraded to Outperform from Sector Perform at RBC Capital » 21:21
03/10/20
03/10
21:21
03/10/20
21:21
CHE

Chemed

$413.37 /

+19.41 (+4.93%)

RBC Capital analyst Frank…

RBC Capital analyst Frank Morgan upgraded Chemed to Outperform from Sector Perform with a price target of $535, up from $448. The recent market pullback provides an attractive entry point into the shares, Morgan tells investors in a research note. Both hospice and drain cleaning are largely immune to the coronavirus and a slowing U.S. economy, adds the analyst. Morgan likes the "predictable demand" in Chemed's two segments, Roto-Rooter and hospice, as well as its "strong financial position and strong cash flow."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Recommendations
Chemed price target raised to $525 from $535 at Oppenheimer » 08:14
02/19/20
02/19
08:14
02/19/20
08:14
CHE

Chemed

$492.13 /

+2.12 (+0.43%)

Oppenheimer analyst…

Oppenheimer analyst Michael Wiederhorn raised his price target for Chemed to $535 from $525 after the company reports Q4 beat and "robust" 2020 guidance. The analyst has an Outperform rating on the shares.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Chemed sees FY20 adjusted EPS $16.20-$16.50, consensus $15.63 » 16:20
02/18/20
02/18
16:20
02/18/20
16:20
CHE

Chemed

$492.13 /

+2.12 (+0.43%)

Revenue growth for VITAS…

Revenue growth for VITAS in 2020, prior to Medicare Cap, is estimated to be in the range of 8.5% to 9.5%. Roto-Rooter is forecasted to achieve full-year 2020 revenue growth of 13.0% to 14.0%. Based upon the revenue outlooks and other assumptions, full-year 2020 adjusted earnings per diluted share, excluding non-cash expense for stock options, tax benefits from stock options, costs related to litigation, intangible amortization of reacquired franchise rights and other discrete items, is estimated to be in the range of $16.20 to $16.50.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Chemed reports Q4 adjusted EPS $4.22, consensus $4.09 » 16:18
02/18/20
02/18
16:18
02/18/20
16:18
CHE

Chemed

$492.13 /

+2.12 (+0.43%)

Reports Q4 revenue $522M,…

Reports Q4 revenue $522M, consensus $524.19M.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a quarter ago
Recommendations
Chemed price target raised to $470 from $440 at Oppenheimer » 07:45
11/25/19
11/25
07:45
11/25/19
07:45
CHE

Chemed

$426.73 /

+3.73 (+0.88%)

Oppenheimer analyst…

Oppenheimer analyst Michael Wiederhorn raised his price target for Chemed to $470 from $440 and maintained an Outperform rating after attending meetings with Chemed management, saying he believes the story remains on track as the re-basing benefit is set to take effect starting in Q4. Additionally, the analyst tells investors in a research note that Chemed continues to generate strong organic growth trends, supported by strong cash flow and compelling capital deployment trends.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Chemed management to meet with Oppenheimer » 04:55
11/20/19
11/20
04:55
11/20/19
04:55
CHE

Chemed

$421.00 /

+6.3 (+1.52%)

Meetings to be held in…

Meetings to be held in Boston on November 18 in Toronto on November 19 and in New York on November 20 hosted by Oppenheimer.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Chemed management to meet with Oppenheimer » 07:29
11/19/19
11/19
07:29
11/19/19
07:29
CHE

Chemed

$414.70 /

+7.7 (+1.89%)

Meetings to be held in…

Meetings to be held in Boston on November 18 in Toronto on November 19 and in New York on November 20 hosted by Oppenheimer.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Chemed upgraded to Outperform at JMP Securities on stable hospice outlook » 06:11
11/01/19
11/01
06:11
11/01/19
06:11
CHE

Chemed

$396.96 /

-4.39 (-1.09%)

JMP Securities analyst…

JMP Securities analyst Peter Martin upgraded Chemed to Outperform from Market Perform with a $490 price target. The analyst sees the outlook for hospice reimbursement as "stable" and also expects the labor cost increases to subside. Martin further notes that given the growth of water restoration and commercial services, Chemed's plumbing division should not see the downside in EBITDA that the company experienced during the last recession.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Chemed upgraded to Outperform from Market Perform at JMP Securities » 05:48
11/01/19
11/01
05:48
11/01/19
05:48
CHE

Chemed

$396.96 /

-4.39 (-1.09%)

JMP Securities analyst…

JMP Securities analyst Peter Martin upgraded Chemed to Outperform from Market Perform with a $490 price target.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.